Stage
Series B | AliveTotal Raised
$7MLast Raised
$7M | 28 yrs agoAbout Biopsys Medical
News of a breast biopsy raises many emotions and concerns. The company understand. But it's important to remember that 80% of breast biopsies do not turn out to be breast cancer. It's also important to know that users have options when selecting a biopsy procedure. This site is dedicated to evaluating their choices to help users talk with their doctor about the breast biopsy procedure that is right for users. One of those choices is a minimally invasive breast biopsy for breast cancer diagnosis using the Mammotome Breast Biopsy System. Mammotome is made available by Ethicon Endo-Surgery, Inc.
Missing:Biopsys Medical'sProduct Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing:Biopsys Medical'sProduct & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Biopsys MedicalFrequently Asked Questions (FAQ)
What is Biopsys Medical's latest funding round?
Biopsys Medical's latest funding round is Series B.
How much did Biopsys Medical raise?
Biopsys Medical raised a total of $7M.
Who are the investors of Biopsys Medical?
Investors of Biopsys Medical include Three Arch Partners.
Who are Biopsys Medical's competitors?
Competitors of Biopsys Medical include Gynesonics, Monteris Medical, Intact Medical, PEAK Surgical, SenoRx and 12 more.
Compare Biopsys Medical to Competitors
Pro-Duct Health is a medical device company focused on developing and commercializing products for non-invasive detection of breast cancer.
PreMD Inc. is dedicated to saving and improving people's lives with simple, painless and patient-friendly tests that can detect life-threatening illnesses at a. The company's tests do not require any patient preparation or dietary restrictions and can be performed at the point of care, in a laboratory setting and, in some cases, even at home. The company's cardiovascular risk assessment technology, PREVU* Skin Sterol Test, assesses a patient's risk of heart disease by non-invasively measuring the amount of cholesterol in the skin tissues. PreMD's non- or minimally-invasive tests for early-stage colorectal, lung and breast cancers detect a cancer-associated sugar in a sample of rectal mucus, sputum and breast nipple aspirate fluid, respectively. The company's cancer tests are in development.
RadioTherapeutics Corporation is developing tools for minimally invasive treatment of solid tumors. The RF 2000B is used by surgeons, interventional radiologists, and gastroenterologists to predictably, precisely and homogeneously ablate diseased or unwanted volumes of soft tissues.
Abla-Tx t公司是一家私人公司成立於2005年o develop a software based algorithm to monitor thermal ablation of tumors. Abla-Tx has been formed to help guide minimally invasive methods for the treatment of all malignant and benign solid tumors. A patented method of monitoring temperature during thermal ablation in conjunction with CT and digital x-ray imaging will be developed and commercialized. Regulatory approval will be sought to allow the sale of a software based thermal mapping system that will be used in conjunction with CT and planar x-ray imaging systems.
Windy Hill Medical is a medical device and pharmaceutical company focused on the development of products to reduce the risk of developing breast cancer in patients deemed to be at high risk.
US HIFU, LLC is a privately held health care company focused on treating primary and recurrent prostate cancer using HIFU, a minimally invasive outpatient procedure which potentially improves patients quality of life. US HIFU was founded in 2004 and is headquartered in Charlotte, N.C.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.